login
login

Europe Daily Bulletin No. 8771

26 August 2004
Contents Publication in full By article 25 / 34
ECONOMIC INTERPENETRATION / (eu) biotechnology

German company BAYER has hived off its biotech respiratory drug projects into a new company called AEROVANCE, funded to the tune of USD 32 billion by a group of investors led by APAX PARTNERS. BAYER will hold a 19.9% stake in AEROVANCE. AEROVANCE will hold the rights to two lead BAYER projects, for asthma and smoker's lung.

Contents

THE DAY IN POLITICS
GENERAL NEWS
ECONOMIC INTERPENETRATION